SX-682 is another novel potent inhibitor of CXCR1/2 (22, 71) and recently being investigated in many clinical trials in several cancer types such as melanoma, colorectal cancer, and breast cancer (NCT03161431, NCT04574583, and NCT04245397). This evidence concerns the gene CXCR1 and breast carcinoma.